Trial Profile
An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Artesunate (Primary) ; Imatinib (Primary) ; Infliximab (Primary) ; Interferon beta-1a (Primary) ; Remdesivir (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Acronyms SOLIDARITY; Solidarity PLUS
- 11 May 2023 The study has been suspended in Latvia and Portugal, according to European Clinical Trials Database record.
- 15 Sep 2022 Results published in the Gilead Sciences Media Release.
- 15 Sep 2022 According to a Gilead Sciences media release, full results from this trial were published in May 2022.